Needham & Company LLC Estimates Teleflex Q2 Earnings

Teleflex Incorporated (NYSE:TFX) – Stock analysts at Needham & Company LLC issued their Q2 2026 earnings estimates for Teleflex in a research report issued on Friday, May 8th. Needham & Company LLC analyst M. Matson forecasts that the medical technology company will post earnings per share of $1.28 for the quarter. Needham & Company LLC has a “Buy” rating and a $147.00 price objective on the stock. The consensus estimate for Teleflex’s current full-year earnings is $6.80 per share. Needham & Company LLC also issued estimates for Teleflex’s Q3 2026 earnings at $1.72 EPS, Q4 2026 earnings at $2.01 EPS, FY2026 earnings at $6.40 EPS, Q1 2027 earnings at $2.72 EPS, Q2 2027 earnings at $2.80 EPS, Q3 2027 earnings at $2.74 EPS, Q4 2027 earnings at $3.07 EPS and FY2027 earnings at $11.33 EPS.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. During the same quarter last year, the company posted $1.44 EPS. The firm’s quarterly revenue was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.

TFX has been the subject of several other research reports. Wall Street Zen lowered shares of Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday. Raymond James Financial restated an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a research note on Friday. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Wells Fargo & Company boosted their target price on Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Finally, Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 target price on the stock in a research note on Monday, April 13th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Teleflex currently has an average rating of “Hold” and a consensus target price of $144.00.

Teleflex Price Performance

TFX opened at $129.00 on Wednesday. The firm has a market cap of $5.71 billion, a price-to-earnings ratio of -5.66, a PEG ratio of 0.95 and a beta of 0.82. The company has a current ratio of 2.55, a quick ratio of 2.03 and a debt-to-equity ratio of 0.82. The stock’s 50-day moving average price is $120.22 and its 200 day moving average price is $116.70. Teleflex has a 12-month low of $100.18 and a 12-month high of $139.67.

Institutional Trading of Teleflex

Several institutional investors and hedge funds have recently made changes to their positions in TFX. PNC Financial Services Group Inc. grew its stake in Teleflex by 11.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 17,346 shares of the medical technology company’s stock worth $2,075,000 after buying an additional 1,759 shares during the last quarter. Heartland Advisors Inc. lifted its stake in Teleflex by 107.8% in the first quarter. Heartland Advisors Inc. now owns 215,998 shares of the medical technology company’s stock valued at $25,836,000 after buying an additional 112,071 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Teleflex by 30.5% in the first quarter. Bessemer Group Inc. now owns 47,798 shares of the medical technology company’s stock valued at $5,718,000 after acquiring an additional 11,180 shares during the period. Illinois Municipal Retirement Fund grew its position in shares of Teleflex by 17.1% during the first quarter. Illinois Municipal Retirement Fund now owns 24,596 shares of the medical technology company’s stock worth $2,942,000 after acquiring an additional 3,591 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Teleflex by 2.0% during the first quarter. Principal Financial Group Inc. now owns 214,193 shares of the medical technology company’s stock worth $25,620,000 after acquiring an additional 4,214 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date was Friday, March 6th. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.

More Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Needham & Company reiterated a Buy rating and set a $147 price target, while also forecasting strong future earnings growth, including FY2028 EPS of $12.18 and Q1 2028 EPS of $2.90. Teleflex analyst estimate report
• Positive Sentiment: Citizens JMP published bullish multi-year estimates for Teleflex, projecting FY2027 EPS of $10.50 and quarterly EPS progression through 2027, suggesting confidence in the company’s earnings trajectory. Teleflex analyst estimate report
• Neutral Sentiment: Truist Financial reaffirmed its Hold rating but raised its price target to $143 from $135, signaling a somewhat improved valuation view without a full bullish upgrade. Teleflex hold rating reaffirmed at Truist Financial
• Neutral Sentiment: Analyst consensus for Teleflex’s current fiscal year remains around $6.75-$6.80 EPS, which provides a stable backdrop but does not by itself signal a new catalyst. Teleflex analyst estimate report

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.